x

Posted 01 April, 2024

2seventy bio, Inc. appointed new CEO

CEO Change detected for ticker Nasdaq:TSVT in a 8-K filed on 01 April, 2024.


  As disclosed on January 30, 2024, in connection with Nick Leschly's resignation as the Company's president and chief executive officer, Mr. Leschly and the Company entered into a Transitional Services Agreement, effective as of the closing of the Asset Sale (the "Transition Agreement").  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of 2seventy bio, Inc.
Health Care/Life Sciences • Biotechnology
2seventy Bio, Inc. operates as cell and gene therapy company. It is focused on the research, development, and commercialization of transformative treatments for cancer. The company was founded on April 26, 2021 and is headquartered in Cambridge, MA.
Market Cap
$235M
View Company Details
2seventy bio, Inc. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain 

Officers; Compensatory Arrangements of Certain Officers.


As disclosed on January 30, 2024, in connection with Nick Leschly's resignation as the Company's president and chief executive officer, Mr. Leschly and the Company entered into a Transitional Services Agreement, effective as of the closing of the Asset Sale (the "Transition Agreement"). On March 29, 2024, Mr. Leschly and the Company entered into an Amended and Restated Transitional Services Agreement (the "Amended Transition Agreement") to clarify that Mr. Leschly will remain eligible as an employee under the Company's benefit plans for so long as he is serving as Chairman of the board of directors. 


The foregoing description of the Amended Transition Agreement is qualified in its entirety by the complete text of the Amended Transition Agreement, a copy of which is filed with this Current Report on Form 8-K as Exhibit 10.1 and incorporated herein by reference.